Skip to main content
    B

    bioAffinity Technologies, Inc. (BIAF)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $2.00
    -0.20 (-9.09%)

    Market Cap: $4.00M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    bioAffinity Technologies, Inc. (BIAF) Financials: Revenue, Profit and Cash Flow

    Updated Nov 6, 2026. Financial statements from company filings, amounts in US dollars.

    bioAffinity Technologies reported revenue of $6.16M for the fiscal year ended Dec 31, 2025, down 34.2% from the year before. That year, net income was -$14.91M with a net margin of -242.0%, operating cash flow was -$9.33M and free cash flow was -$9.39M. The quarter ended Sep 30, 2026 had revenue of $1.07M and net income of -$5.28M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$6.16M-34.2%100.0%-171.6%-242.0%
    Dec 2024$9.36M+269.7%100.0%-95.6%-96.6%
    Dec 2023$2.53M+52627.4%100.0%-314.8%-313.4%
    Dec 2022$4.80KN/A100.0%-83511.5%-169771.2%
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$6.16M$9.36M$2.53M$4.80K$0$0N/A
    Cost of revenue$0$0$0$0$0$22.24K$40.28K
    Gross profit$6.16M$9.36M$2.53M$4.80K$0-$22.24K-$40.28K
    Research and development$2.09M$1.78M$1.72M$1.52M$1.14M$1.61M$1.85M
    Operating income-$10.57M-$8.95M-$7.97M-$4.01M-$2.21M-$2.60M-$3.09M
    Net income-$14.91M-$9.04M-$7.94M-$8.15M-$6.33M-$7.27M-$3.31M
    EBITDAN/A-$8.35M-$7.75M-$4.00MN/AN/A-$3.05M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.07M$1.51M$1.35M$1.59M$1.45M$1.27M$1.85M$2.21M$2.35M$2.40M$2.41M$2.21M
    Gross profit$1.07M$1.51M$1.35M$1.59M$1.45M$1.27M$1.85M$2.21M$2.35M$2.40M$2.41M$2.21M
    Operating income-$3.51M-$3.33M-$3.62M-$3.14M-$2.29M-$2.52M-$2.63M-$2.95M-$1.97M-$2.09M-$1.95M-$2.34M
    Net income-$5.28M-$3.37M-$3.63M-$3.14M-$5.05M-$4.06M-$2.66M-$2.97M-$2.00M-$2.11M-$1.96M-$2.37M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $146.47K by $6.30M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$10.96M$6.51M$8.22M$12.18M$1.45M$145.60K$658.81K
    Current assets$7.57M$2.70M$3.97M$11.96M$1.44M$118.66K$617.51K
    Cash and equivalents$6.45M$1.11M$2.82M$11.41M$1.36M$83.11K$578.48K
    Total liabilities$3.68M$3.91M$3.37M$1.14M$13.20M$15.22M$4.69M
    Short-term debt$105.16K$171.67K$0$251.75K$11.15M$9.95M$4.01M
    Long-term debt$41.31K$20.18K$0N/A$160.18K$53.47KN/A
    Shareholder equity$7.28M$2.60M$4.86M$11.04M-$15.79M-$15.07M-$4.04M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$7.55M$7.62M$7.95M$10.96M$11.55M$4.75M$5.55M$6.51M$6.55M$6.66M$8.05M$8.22M
    Total liabilities$3.64M$3.85M$4.28M$3.68M$2.64M$6.89M$4.11M$3.91M$3.43M$3.22M$2.79M$3.37M
    Cash and equivalents$2.55M$2.43M$3.10M$6.45M$7.67M$802.84K$444.71K$1.11M$756.58K$801.31K$2.45M$2.82M
    Shareholder equity$3.91M$3.77M$3.66M$7.28M$8.90M-$2.14M$1.44M$2.60M$3.12M$3.43M$5.26M$4.86M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$9.33M-$7.26M-$6.04M-$4.07M-$2.05M-$2.21M-$2.49M
    Capital expenditures$60.57K$79.08K$22.90K$219.99K$0$2.89K$11.40K
    Free cash flow-$9.39M-$7.34M-$6.06M-$4.29M-$2.05M-$2.21M-$2.50M
    Dividends paidN/AN/AN/A$185N/AN/AN/A
    Share repurchases$1.77M$1.26MN/AN/AN/AN/AN/A
    Investing cash flow-$60.57K-$79.08K-$2.21M-$219.99K$0-$2.89K-$11.40K
    Financing cash flow$14.73M$5.63M-$344.98K$14.34M$3.33M$1.72M$2.33M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$3.87M-$3.20M-$3.23M-$2.56M-$2.48M-$2.65M-$1.64M-$1.68M-$1.71M-$1.53M-$2.35M-$1.62M
    Capital expenditures$77.05K$89.97K$5.66K$1$3.65K$13.43K$50.79K$1$9.41K$28.29K$41.39K$13.44K
    Free cash flow-$3.95M-$3.29M-$3.23M-$2.56M-$2.48M-$2.66M-$1.69M-$1.68M-$1.72M-$1.56M-$2.39M-$1.63M
    Last 12 quarters

    Frequently Asked Questions About BIAF

    What is bioAffinity Technologies' annual revenue?

    bioAffinity Technologies reported revenue of $6.16M for the fiscal year ended Dec 31, 2025.

    How fast is bioAffinity Technologies' revenue growing?

    Revenue was down 34.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 986.6%.

    Is bioAffinity Technologies profitable?

    No. bioAffinity Technologies reported net income of -$14.91M for the fiscal year ended Dec 31, 2025, with a net margin of -242.0%.

    How much free cash flow does BIAF generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$9.33M minus capital expenditures of $60.57K produced free cash flow of -$9.39M.

    How much debt does bioAffinity Technologies have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $41.31K, short-term debt of $105.16K and cash and equivalents of $6.45M.